147 related articles for article (PubMed ID: 38439724)
41. [Sebaceous gland tumor with a rare gene mutation within a tumor syndrome: Muir-Torre syndrome].
Voigt E; Sommer F; Geiger KD; Pillunat LE
Ophthalmologe; 2014 Apr; 111(4):369-72. PubMed ID: 23774967
[TBL] [Abstract][Full Text] [Related]
42. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
[TBL] [Abstract][Full Text] [Related]
43. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
44. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
45. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
46. The DNA mismatch repair system in sebaceous tumors: an update on the genetics and workup of Muir-Torre syndrome.
Dany M
Cutis; 2020 Mar; 105(3):E34-E37. PubMed ID: 32352449
[TBL] [Abstract][Full Text] [Related]
47. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
48. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
49. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
50. [Muir-Torre syndrome associated with Waldenstrom's macroglobulinemia].
Velter C; Bourlond F; Wettle C; Lioure B; Lipsker D; Maugard C; Cribier B
Ann Dermatol Venereol; 2016 Dec; 143(12):825-830. PubMed ID: 27771121
[TBL] [Abstract][Full Text] [Related]
51. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
52. Sebaceous neoplasms and the Muir-Torre syndrome.
Elston DM
J Am Acad Dermatol; 2023 Dec; 89(6):1123. PubMed ID: 37172735
[No Abstract] [Full Text] [Related]
53. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
54. [Muir-Torre syndrome. An interdisciplinary challenge].
Anders D; Kneitz H; Kunstmann E; Bröcker EB; Benoit S
Hautarzt; 2012 Mar; 63(3):226-9. PubMed ID: 21858561
[TBL] [Abstract][Full Text] [Related]
55. A case of Muir-Torre syndrome with a keratoacanthoma and sebaceous neoplasms: Clinicopathological features and a speculation on the pathogenesis of cutaneous tumor type.
Takayama E; Yoshioka A; Takai T; Goto K
J Dermatol; 2021 May; 48(5):690-694. PubMed ID: 33523490
[TBL] [Abstract][Full Text] [Related]
56. [Muir-Torre syndrome].
Kudibal MT; Venzo A
Ugeskr Laeger; 2018 Jul; 180(27):. PubMed ID: 29984696
[TBL] [Abstract][Full Text] [Related]
57. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
58. A Case of Muir-Torre Syndrome.
Sheth R; Menon P; Malik D
Cureus; 2021 Apr; 13(4):e14582. PubMed ID: 34036002
[TBL] [Abstract][Full Text] [Related]
59. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
[TBL] [Abstract][Full Text] [Related]
60. Ocular Adnexal Adenomatoid Sebaceous Gland Hyperplasia: A Clinical and Immunopathologic Analysis in Relation to the Muir-Torre Syndrome.
Jakobiec FA; Cortes Barrantes P; Milman T; Lee NG; Fay A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):e6-e12. PubMed ID: 31593035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
